Mussels, Inflammation and Rheumatoid Arthritis (MIRA)
MIRA
1 other identifier
interventional
23
1 country
1
Brief Summary
Rheumatoid arthritis (RA) is a chronic disease that affects \~1% of the population. A large proportion of patients with established disease have persistent high disease activity in spite of existing effective pharmacological treatment. Improved treatment is thus urgently needed, including alternative treatments in addition to optimal pharmacological therapy. The main purpose of this study is to investigate if a high intake of blue mussel (Mytilus Edulis) could decrease inflammation and disease activity in patients with established RA. A secondary goal is to identify novel biomarkers for blue mussel intake and metabolic responses to this diet, using a metabolomics approach with high sensitivity and specificity. A third goal is to look at genetic polymorphisms in relation to long chain polyunsaturated fatty acids (LCPUFA) and inflammatory markers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable rheumatoid-arthritis
Started Aug 2015
Shorter than P25 for not_applicable rheumatoid-arthritis
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 29, 2015
CompletedStudy Start
First participant enrolled
August 1, 2015
CompletedFirst Posted
Study publicly available on registry
August 13, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2016
CompletedNovember 19, 2024
November 1, 2024
9 months
April 29, 2015
November 15, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
difference between disease activity score 28 (DAS28) after the diets
Measured clinically
after 11 week intervention
Secondary Outcomes (3)
difference in inflammatory markers/cytokines (IL-1beta, IL-6, Tumor Necrosis Factor-alfa, IL-10) after the diets
after 11 week intervention
Difference in Quality of life and health by SF36, EQ5D och HAQ after the diets
after 11 week intervention
Differences and changes in metabolites after the two diets
after 11 week intervention
Other Outcomes (5)
Difference in plasma and RBC fatty acids after the diets and changes during the diets
after 11 week intervention
Differences between blood lipids (TAG, HDL, LDL) after the diets
after 11 week intervention
Differences in Hb after the diets
after 11 week intervention
- +2 more other outcomes
Study Arms (2)
Blue mussel diet
EXPERIMENTAL5 meals a week including blue mussels
Meat/control diet
ACTIVE COMPARATOR5 meals a week including meat
Interventions
Eligibility Criteria
You may qualify if:
- BMI 18-40 kg/m2,
- disease duration \>2 years,
- DAS28 \>3.0
You may not qualify if:
- other Life-threatening disease,
- pregnant,
- lactating,
- food intolerant or allergic to food included in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Göteborg Universitylead
- Sahlgrenska University Hospitalcollaborator
Study Sites (1)
Sahlgrenska University Hospital
Gothenburg, Not in US/Canada, 405 30, Sweden
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Helen M Lindqvist, PhD
Göteborg University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- CARE PROVIDER, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 29, 2015
First Posted
August 13, 2015
Study Start
August 1, 2015
Primary Completion
May 1, 2016
Study Completion
May 1, 2016
Last Updated
November 19, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share
Not approved by the Ethical Review board